NEKTAR THERAPEUTICS Income Statement
NKTR / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
NEKTAR THERAPEUTICS reported $55M in revenue and $164M in net loss for FY2025. Revenue has declined at a 1.9% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55.2M | $90.1M | $101.9M | $92.1M | $101.9M | $1.2B | $307.7M | $165.4M | $24.7M | $200.7M | $230.8M | $81.2M | $71.5M | $159.0M | $71.9M |
| Cost of Revenue | $0 | $33.8M | $24.9M | $21.6M | $24.9M | $24.4M | $30.5M | $30.2M | $30.5M | $28.5M | $34.1M | $30.4M | $21.9M | $25.7M | $30.9M |
| SG&A Expense | $68.7M | $77.4M | $122.8M | $92.3M | $122.8M | $81.4M | $52.4M | $44.3M | $52.4M | $40.9M | $43.3M | $41.6M | $46.8M | $41.0M | $41.0M |
| R&D Expense | $117.3M | $114.2M | $400.3M | $218.3M | $400.3M | $399.5M | $268.5M | $203.8M | $268.5M | $147.7M | $182.8M | $148.7M | $126.8M | $108.1M | $95.1M |
| Operating Income | -$140.1M | -$263.7M | -$446.1M | -$376.2M | -$446.1M | $687.9M | -$59.6M | -$112.9M | -$59.6M | -$16.5M | -$29.4M | -$141.2M | -$123.9M | -$28.3M | -$95.1M |
| Interest Expense | - | - | - | $0 | $0 | $21.6M | $22.1M | $22.5M | $22.1M | $17.9M | $18.3M | $15.5M | $10.2M | $11.2M | $12.2M |
| Income Tax | -$138.0K | -$200.0K | $557.0K | $3.2M | $557.0K | $1.4M | $616.0K | $876.0K | $616.0K | -$512.0K | $506.0K | $406.0K | $1.0M | $881.0K | -$253.0K |
| Net Income | -$164.1M | -$276.1M | -$523.8M | -$368.2M | -$523.8M | $681.3M | -$96.7M | -$153.5M | -$96.7M | -$53.9M | -$81.2M | -$171.9M | -$134.0M | -$37.9M | -$102.5M |
| EPS (Basic) | -$8.68 | -$1.45 | -$2.86 | -$2.49 | -$2.52 | $4.02 | -$0.62 | -$1.10 | -$0.42 | -$0.14 | $0.26 | -$0.37 | - | - | - |
| EPS (Diluted) | -$8.68 | -$1.45 | -$2.86 | -$2.49 | -$2.52 | $3.78 | -$0.62 | -$1.10 | -$0.42 | -$0.14 | $0.25 | -$0.37 | -$1.19 | -$0.40 | -$1.11 |
| Shares Outstanding | 12.4M | 191.4M | 188.6M | 185.5M | 180.1M | 176.5M | 173.5M | 159.5M | 153.2M | 135.3M | 131.2M | 116.5M | 115.3M | 114.5M | 94.5M |
| Operating Margin | -253.7% | -292.6% | -437.8% | -408.6% | -437.8% | 57.6% | -19.4% | -68.2% | -241.2% | -8.2% | -12.7% | -173.9% | -173.4% | -17.8% | -132.3% |
| Profit Margin | -297.1% | -306.3% | -514.0% | -400.0% | -514.0% | 57.1% | -31.4% | -92.8% | -391.0% | -26.9% | -35.2% | -211.7% | -187.4% | -23.8% | -142.5% |